Profile change history

What changed for Carfilzomib?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Carfilzomib identity.

62Total events
62Record additions
0Version changes
10Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 62 connected records →

Showing the latest 62 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 17, 2026.

Record added

ClinicalTrials.gov record NCT03606577

PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06152575

PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07555938

PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07715903

PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Record added

Federal Register notice 2012-10154

The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
April 27, 2012
Evidence lane
Regulatory
Record added

Federal Register notice 2014-11175

The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
May 15, 2014
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT01080391

PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
September 21, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01302392

PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
May 2, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01559935

PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
September 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01568866

PeptideScanner retained ClinicalTrials.gov record NCT01568866 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-11-14, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
November 14, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01572480

PeptideScanner retained ClinicalTrials.gov record NCT01572480 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
March 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01813227

PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
April 3, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01816971

PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
April 21, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01818752

PeptideScanner retained ClinicalTrials.gov record NCT01818752 at 2026-11-16T17:39:29.005Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
August 26, 2019
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02412878

PeptideScanner retained ClinicalTrials.gov record NCT02412878 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-23, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
September 23, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02773030

PeptideScanner retained ClinicalTrials.gov record NCT02773030 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
March 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02937571

PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
November 20, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02969837

PeptideScanner retained ClinicalTrials.gov record NCT02969837 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-01-16, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
January 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03029234

PeptideScanner retained ClinicalTrials.gov record NCT03029234 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
May 25, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03158688

PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
May 9, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03275285

PeptideScanner retained ClinicalTrials.gov record NCT03275285 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-02-09, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
February 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03290950

PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
May 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03412565

PeptideScanner retained ClinicalTrials.gov record NCT03412565 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-04-29, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
April 29, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03416374

PeptideScanner retained ClinicalTrials.gov record NCT03416374 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-27, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
September 27, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03859427

PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
August 13, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03934684

PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
May 11, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04191616

PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
September 4, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04430894

PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
October 6, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04756401

PeptideScanner retained ClinicalTrials.gov record NCT04756401 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
September 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04925193

PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
October 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05497804

PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 16, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.

PubMed lists PMID 34647444 in Haematologica as Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 27, 2026
Evidence lane
Literature metadata
Record added

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with…

PubMed lists PMID 34774221 in The Lancet. Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 10, 2022
Evidence lane
Literature metadata
Record added

Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.

PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 29, 2026
Evidence lane
Literature metadata
Record added

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.

PubMed lists PMID 36073950 in Japanese journal of clinical oncology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.

PubMed lists PMID 36372355 in Transplantation and cellular therapy as Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.

PubMed lists PMID 36375132 in Blood advances as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…

PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata
Record added

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a r…

PubMed lists PMID 36642080 in The Lancet. Oncology as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-01-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.

PubMed lists PMID 36763537 in Blood advances as Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.

PubMed lists PMID 37479547 in Clinical lymphoma, myeloma & leukemia as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-03 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.

PubMed lists PMID 37584290 in Haematologica as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 23, 2024
Evidence lane
Literature metadata
Record added

Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell L…

PubMed lists PMID 37632592 in Targeted oncology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-26 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomi…

PubMed lists PMID 37691005 in British journal of haematology as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.

PubMed lists PMID 37717583 in The Lancet. Oncology as Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
March 24, 2026
Evidence lane
Literature metadata
Record added

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide al…

PubMed lists PMID 38747414 in Polish archives of internal medicine as Journal Article, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 14, 2024
Evidence lane
Literature metadata
Record added

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.

PubMed lists PMID 38811560 in Blood cancer journal as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-29 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 7, 2024
Evidence lane
Literature metadata
Record added

Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.

PubMed lists PMID 38938122 in British journal of haematology as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 30, 2025
Evidence lane
Literature metadata
Record added

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

PubMed lists PMID 39576965 in Blood advances as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-02-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
June 3, 2025
Evidence lane
Literature metadata
Record added

Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.

PubMed lists PMID 39638553 in European journal of haematology as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2024-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
June 5, 2025
Evidence lane
Literature metadata
Record added

Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management.

PubMed lists PMID 40213696 in Frontiers in pharmacology as Journal Article, Review, with publication-date metadata of 2025-03-27 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
April 12, 2025
Evidence lane
Literature metadata
Record added

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 13, 2026
Evidence lane
Literature metadata
Record added

Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.

PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 6, 2025
Evidence lane
Literature metadata
Record added

Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.

PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 9, 2026
Evidence lane
Literature metadata
Record added

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

PubMed lists PMID 41719502 in Blood advances as Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 26, 2026
Evidence lane
Literature metadata
Record added

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

PubMed lists PMID 41942646 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-04-06 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata